During the first cycle of pemigatinib 13.5 mg for FGFR2-rearranged cholangiocarcinoma, an asymptomatic patient has serum phosphate 8.2 mg/dL for the

Question

During the first cycle of pemigatinib 13.5 mg for FGFR2-rearranged cholangiocarcinoma, an asymptomatic patient has serum phosphate 8.2 mg/dL for the first time. No phosphate-lowering treatment has yet been used. What is the licensed initial management?

Accepted Answer

Continue pemigatinib, start phosphate-lowering therapy and monitor serum phosphate weekly

Answer

Withhold pemigatinib immediately and restart one dose level lower below 7 mg/dL

Answer

Continue pemigatinib and defer intervention until phosphate exceeds 10 mg/dL

Answer

Permanently discontinue pemigatinib because phosphate is above 7 mg/dL

Answer

Reduce pemigatinib immediately and add calcitriol to prevent hypocalcaemia

Gastric Cancer — SCE Medical Oncology MCQ

During the first cycle of pemigatinib 13.5 mg for FGFR2-rearranged cholangiocarcinoma, an asymptomatic patient has serum phosphate 8.2 mg/dL for the first time. No phosphate-lowering treatment has yet been used. What is the licensed initial management?